U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Methotrexate Sodium Injection
Status: Currently in Shortage
»Date first posted: 03/13/2023
»Therapeutic Categories: Rheumatology; Oncology

Expand all

Accord Healthcare Inc. (Revised 09/01/2026)

Company Contact Information:
866-941-7875, option 2

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) Unavailable Fresh batch est avail Sep Week 3; ACC has short dated inventory with expiry of 09/30/27 Other
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) Unavailable ACC has short dated inventory with expiry of 08/31/27; Fresh inventory plan TBD Other

Fresenius Kabi USA, LLC (Reverified 09/01/2026)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) Available Check wholesaler for inventory
Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10) Available Check wholesaler for inventory

Hikma Pharmaceuticals USA, Inc. (Reverified 09/03/2026)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01) Unavailable Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. Demand increase for the drug
Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) Unavailable Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc., a Pfizer Company (Reverified 08/24/2026)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) Available
Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10) Available
Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41) Available
Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) Available
Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) Available

Teva Pharmaceuticals USA, Inc. (Revised 09/01/2026)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) Available
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) Limited Availability Estimated recovery: December 2026 Other
Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) Limited Availability Estimated recovery: October 2026 Other
Back to Top